Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy

2017 ◽  
Vol 30 (6) ◽  
pp. 719-727 ◽  
Author(s):  
Giacomo Garibotto ◽  
Annalisa Carta ◽  
Daniela Picciotto ◽  
Francesca Viazzi ◽  
Daniela Verzola
2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Monica Molteni ◽  
Sabrina Gemma ◽  
Carlo Rossetti

Toll-like receptor 4 (TLR4) belongs to the family of pattern recognition receptors (PRRs). They are highly conserved receptors that recognize conserved pathogen-associated molecular patterns (PAMPs), thus representing the first line of defense against infections. TLR4 has been long recognized as the sensing receptor for gram-negative lipopolysaccharide (LPS). In addition, it also binds endogenous molecules produced as a result of tissue injury. Hence, TLR4 represents a key receptor on which both infectious and noninfectious stimuli converge to induce a proinflammatory response. TLR4-mediated inflammation, triggered by exogenous or endogenous ligands, is also involved in several acute and chronic diseases, having a pivotal role as amplifier of the inflammatory response. This review focuses on the research progress about the role of TLR4 activation in infectious and noninfectious (e.g., sterile) inflammation and the effects of TLR4 signaling in some pathological conditions.


Diabetologia ◽  
2012 ◽  
Vol 55 (8) ◽  
pp. 2256-2266 ◽  
Author(s):  
T. Kuwabara ◽  
K. Mori ◽  
M. Mukoyama ◽  
M. Kasahara ◽  
H. Yokoi ◽  
...  

2011 ◽  
Vol 23 (1) ◽  
pp. 86-102 ◽  
Author(s):  
Miao Lin ◽  
Wai Han Yiu ◽  
Hao Jia Wu ◽  
Loretta Y.Y. Chan ◽  
Joseph C.K. Leung ◽  
...  

2014 ◽  
Vol 86 (6) ◽  
pp. 1229-1243 ◽  
Author(s):  
Daniela Verzola ◽  
Laura Cappuccino ◽  
Elena D'Amato ◽  
Barbara Villaggio ◽  
Fabio Gianiorio ◽  
...  

2021 ◽  
Author(s):  
Mona K. Tawfik ◽  
mohammed keshawy ◽  
Samy Makary

Abstract Diabetic nephropathy (DN) is a consequence of diabetes mellitus (DM). DM is associated temporal changes in renal angiotensin II (ANG II) release and multiple mediators leading to DN. These changes were evaluated using early ANG II blocker valsartan as a DN renoprotective drug. Adult male Wister rats were divided into (i) vehicle group; (ii) valsartan received oral 30 mg/Kg/day; (iii) diabetic received single 50 mg/Kg intraperitoneal streptozotocin injection; (iv) renoprotection, valsartan treated-diabetic rats after 7 days from DM. Other group of diabetic animals assigned to receive late valsartan intervention from week 9 to 12 of DM. The renoprotective effect evaluated at 4th, 8th, 12th weeks. DN effects on urine albumin excretion, blood pressure and renal ANG II were measured. Urinary nephrin and kidney injury molecule-1 biomarkers, renal ANGPTL2, and toll-like receptor 4 (TLR 4) mRNA expression were tested. DN-initiated fibrotic markers integrin, α-smooth muscle expression and collagen IV and apoptotic protein caspase 3 were tested. DM induced changes starting from the 4th week. At 12th week, early valsartan intervention showed a significant reduction in ANG II, ANGPTL2 and TLR 4 expression and improvement in albuminuria, blood pressure, urinary biomarkers, fibrotic and apoptotic markers, more than the late intervention. Early inhibition of ANG II in diabetes is associated with decrease in ANGPTL2 and TLR 4 proteins and fibrotic changes. This observation helps in understanding DN pathophysiology and its therapeutic approaches.


PLoS ONE ◽  
2012 ◽  
Vol 7 (9) ◽  
pp. e44100 ◽  
Author(s):  
Mohammed Dehbi ◽  
Taher Uzzaman ◽  
Engin Baturcam ◽  
Abdelmoneim Eldali ◽  
Wilhelmina Ventura ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document